Share This Page
Suppliers and packagers for viltepso
✉ Email this page to a colleague
viltepso
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154 | NDA | NS Pharma, Inc. | 73292-011-01 | 1 VIAL, GLASS in 1 CARTON (73292-011-01) / 1 INJECTION, SOLUTION in 1 VIAL, GLASS | 2020-08-13 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for viltepso
Viltepso (viltolarsen) Suppliers and Manufacturing Sources: Who Makes It, Who Supplies Key Components, and What’s the Supply Chain Footprint?
Viltepso (viltolarsen) is supplied in the US by NS Pharma, Inc. under a program-based distribution model tied to Sarepta Therapeutics. The publicly documented supply chain visibility for API manufacturers, fill-finish partners, and sterile formulation sites for viltepso is limited relative to many large small-molecule products, so the most decision-relevant “supplier” answer for compliance and procurement planning is the commercial supplier of record and distribution entities, plus the single-bottleneck reality of a niche, low-volume biologic-like antisense drug product.
Quick supplier-of-record snapshot (US commercial context)
| Item | Supplier / Entity | Role in supply chain | Evidence level |
|---|---|---|---|
| Drug product commercial supply | NS Pharma, Inc. | US supplier of record / distributor of finished Viltepso | Public labeling/documentation footprint |
| Product sponsor / marketing authorization holder (US) | Sarepta Therapeutics, Inc. | US marketing authorization, product stewardship, payer contracting | Public company/regulatory footprint |
(Underlying API and sterile fill-finish sites are not consistently disclosed in high-level public sources; they typically appear in FDA CMC sections, inspection reports, or vendor capability documents rather than consumer-facing labeling.)
Who supplies Viltepso in the US and who is the supplier of record?
Answer: NS Pharma, Inc. is the supplier/distributor entity for Viltepso in US commercial documentation and labeling; Sarepta Therapeutics is the product sponsor/marketer.
US distribution structure that drives “supplier” decisions
- Supplier of record controls purchase orders, lot release access, and REMS-like operational workflows (even if Viltepso is not a REMS product).
- Sponsor/marketer controls post-marketing commitments and primary regulatory interface.
- For antisense therapies such as viltolarsen, switching either the sterile manufacturing train or critical raw component suppliers typically requires regulatory bridging and can be slow.
Procurement implications
- Contracting typically uses an “order from distributor” model rather than direct API procurement.
- Lot-level availability depends on:
- finished drug release timing,
- shipping lanes (temperature-controlled logistics),
- and capacity at the specific fill-finish/sterile handling sites used for the drug product.
What companies manufacture viltolarsen (API) for Viltepso?
Answer: Public, decision-grade identification of the viltolarsen API manufacturer(s) is not consistently available from widely used, consumer-facing sources (e.g., labeling summaries, press releases). For high-stakes sourcing decisions, API manufacturer identity is typically confirmed through:
- confidential manufacturing arrangements,
- FDA CMC review summaries not always indexed publicly,
- and direct qualification with the supplier of record.
Which fill-finish and sterile drug product suppliers make Viltepso?
Answer: High-confidence public identification of sterile fill-finish sites for Viltepso is not reliably enumerated in consumer-facing documents. Viltepso’s administration profile and manufacturing constraints make it likely that production relies on tightly controlled sterile manufacturing capacity, but site-level public disclosure is limited.
Why sterile fill-finish is the gating item
Viltolarsen is an antisense oligonucleotide requiring:
- controlled sterile processing,
- controlled handling to prevent contamination and degradation,
- validated release testing for oligo integrity and endotoxin/sterility.
In practice, these requirements concentrate manufacturing to a small number of specialized sites, often with limited redundancy.
What suppliers provide excipients and delivery components for Viltepso?
Answer: Public supplier lists for excipients and device components (if any) are not consistently disclosed for Viltepso at a named-vendor level in easily accessible sources.
What “component supplier” planning usually requires for antisense oligos
Procurement for antisense injectables typically hinges on:
- oligo-specific formulation excipients (buffers, tonicity agents),
- sterile filtration materials compatibility,
- primary container closure system specification,
- and shipping/handling materials.
Supplier substitution can require stability and compatibility bridging.
How many manufacturing sites supply Viltepso and what does that mean for supply risk?
Answer: Public sources do not provide a complete and enumerated list of manufacturing sites for Viltepso; therefore, the number of supplying sites is not determinable from high-level accessible records. For business planning, the operative constraint is that Viltepso is a niche therapy, so production is commonly concentrated.
Key supply risk drivers for viltepso
- Oligonucleotide manufacturing and QC release cycle length
- Sterile fill-finish capacity and batch release timing
- Lot availability and distribution constraints due to temperature-controlled logistics
What is the Orange Book status of Viltepso and does it list manufacturing details?
Viltepso is an orphan-designated antisense product. The FDA’s Orange Book is used for small molecule and some biologic “reference” listing, but it does not routinely provide a full “supplier of API and fill-finish” map for complex oligonucleotide products. Orange Book entries, when present for viltepso, typically focus on patents and exclusivity rather than named external manufacturing suppliers.
Operational takeaway: Orange Book helps with patent and exclusivity risk. It does not reliably function as a supplier directory.
Who are the competitive and downstream “supplier” counterparts (generic, biosimilar, and alternative delivery)?
Answer: The competitive “supplier” set for viltepso is constrained by the difficulty of replicating:
- sequence-specific antisense oligo chemistry,
- purification profile,
- and sterile manufacturing system.
As a result, near-term supply competition typically occurs via portfolio-level substitution rather than direct product interchange, unless an approved generic/alternative emerges with the same clinically relevant sequence.
What Viltepso litigation or regulatory issues affect supply and sourcing?
In antisense oligo programs, regulatory and patent disputes more often affect:
- launch timing for competitors,
- payer access and utilization management,
- and potential reformulation/next-gen product pathways.
That can indirectly affect Viltepso supply risk via demand volatility, but it does not normally name manufacturing suppliers in public documents.
Commercial and business-use supplier checklist for Viltepso procurement
Use this checklist for RFPs and vendor qualification when negotiating for continued access to Viltepso:
- Supplier of record contract path: order fulfillment through NS Pharma, Inc.
- Lot-level access: require CoA availability and release documentation for each shipment.
- Storage and logistics: confirm chain-of-custody temperature ranges and shipping container qualification.
- Change control: enforce commitments for notification of any manufacturing site, critical process parameter, or formulation component changes.
- Regulatory bridging: require written commitments that any change will be conducted under approved CMC and will not compromise product quality.
Key Takeaways
- NS Pharma, Inc. is the key supplier/distributor entity for Viltepso in the US supply chain.
- Sarepta Therapeutics is the product sponsor/marketer for Viltepso in the US.
- Public sources do not reliably identify API manufacturers or sterile fill-finish sites by name; supplier confirmation for those layers typically requires direct qualification with the supplier of record or contract-manufacturing disclosure from regulatory/CMC channels.
- For sourcing and continuity planning, the supply-risk focus should be on lot release timing, sterile manufacturing capacity, and change-control governance, not on informal vendor substitution.
FAQs
1) Who is the distributor for Viltepso in the United States?
NS Pharma, Inc. is the US supplier/distributor entity in publicly available commercial documentation.
2) Is there a Viltepso generic or biosimilar supply source?
A direct generic/biosimilar supply substitute is not typically available in the way small molecules are; competitive supply is constrained by antisense sequence specificity and manufacturing complexity.
3) Does the Orange Book list Viltepso manufacturing sites?
Orange Book listings focus on patents and exclusivity, not named API or fill-finish suppliers.
4) What is the main bottleneck risk for viltepso supply?
Sterile drug product manufacturing capacity and lot release timing for an oligonucleotide product.
5) How should a hospital or distributor validate Viltepso shipments?
Require lot-specific CoA, chain-of-custody temperature confirmation, and documented change-control practices covering formulation and manufacturing process integrity.
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drug Label Information for Viltepso (viltolarsen). U.S. Food and Drug Administration.
- Sarepta Therapeutics. Company information and product materials for Viltepso (viltolarsen).
More… ↓
